首页|Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants
Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
Targeted therapy is crucial for advanced colorectal cancer(CRC)positive for genetic drivers.With advances in deep sequencing technology and new targeted drugs,existing standard molecular pathological detection systems and therapeutic strategies can no longer meet the requirements for careful management of patients with advanced CRC.Thus,rare genetic variations require diagnosis and targeted therapy in clinical practice.Rare gene mutations,amplifications,and rearrangements are usually associated with poor prognosis and poor response to conventional therapy.This review summarizes the clinical diagnosis and treatment of rare genetic variations,in genes including erb-b2 receptor tyrosine kinase 2(ERBB2),B-Raf proto-oncogene,serine/threonine kinase(BRAF),ALK receptor tyrosine kinase/ROS proto-oncogene 1,receptor tyrosine kinase(ALK/ROS1),neurotrophic receptor tyrosine kinases(NTRKs),ret proto-oncogene(RET),fibroblast growth factor receptor 2(FGFR2),and epidermal growth factor receptor(EGFR),to enhance understanding and identify more accurate personalized treatments for patients with rare genetic variations.
Shuyi Chen、Jing Gu、Kaichun Wu、Xiaodi Zhao、Yuanyuan Lu
展开 >
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases,Xijing Hospital of Digestive Diseases,Fourth Military Medical University,Xi'an 710032,China
School of Basic Medical Sciences,Fourth Military Medical University,Xi'an 710032,China
NETL
NSTL
万方数据
